Complete Wegovy vs Mounjaro Dosing Cost Breakdown
Wegovy vs Mounjaro Dosing: UK's Lowest Price Advantage
Understanding Wegovy vs Mounjaro dosing costs helps you budget effectively for your weight management journey. EverydayMeds offers the UK's most competitive pricing structure, with Wegovy starting at £79.99 for the 0.25mg starter dose and comprehensive bundle options that reduce your per-pen costs significantly. Unlike many competitors who add consultation fees, delivery charges, or membership costs, our transparent pricing includes everything: clinical assessment, prescriber review, and temperature-controlled next-day delivery.
Our pricing advantage for Wegovy vs Mounjaro dosing extends beyond individual pen costs to include strategic bundle packages designed around each medication's escalation schedule. The Wegovy Intro Trio (0.25mg, 0.5mg, 1mg) covers your first 12 weeks for £299.99, whilst our Mounjaro equivalents follow the tirzepatide 4-step progression. This approach ensures you're never caught short between doses and eliminates the uncertainty of fluctuating individual pen prices during your treatment journey.
Detailed Wegovy vs Mounjaro Dosing Schedules and Pricing
Wegovy follows a structured 5-step dose escalation: 0.25mg (weeks 1-4) at £79.99, 0.5mg (weeks 5-8) at £94.99, 1mg (weeks 9-12) at £99.99, 1.7mg (weeks 13-16) at £139.99, and 2.4mg maintenance from week 17+ at £209.99. Each dose increase occurs monthly, allowing your body to adapt gradually whilst minimising potential side effects. This methodical approach to Wegovy vs Mounjaro dosing ensures optimal tolerance and treatment adherence throughout your weight management programme.
Mounjaro (tirzepatide) uses a more accelerated approach with 4 dose levels over 12 weeks, though specific pricing varies based on current availability. When comparing Wegovy vs Mounjaro dosing costs, consider that Wegovy's longer escalation period may mean more individual purchases but potentially better tolerance. Our discount codes FIRST40 (new customers) and DOSE25 (returning customers) apply at checkout to ensure you always receive our published lowest prices without additional promotional complexity.
Clinical Evidence Behind Wegovy vs Mounjaro Dosing Protocols
The STEP clinical trial programme, including findings published by Wilding et al. in NEJM 2021, demonstrated that Wegovy's 5-step dosing escalation supported an average clinically studied weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity. The gradual dose increases allow patients to adapt to GLP-1 receptor stimulation whilst maintaining treatment adherence throughout the programme.
Mounjaro's dosing schedule reflects its dual GIP/GLP-1 mechanism, with tirzepatide trials showing comparable efficacy using the 4-step escalation approach. When evaluating Wegovy vs Mounjaro dosing based on clinical evidence, both medications require careful dose progression to achieve optimal outcomes whilst minimising gastrointestinal side effects that can occur with too-rapid increases.
How Wegovy's Dosing Schedule Supports Weight Management
Wegovy works as a GLP-1 receptor agonist, mimicking natural hormones that regulate appetite and food intake in your brain's appetite centres. The gradual dose escalation from 0.25mg to 2.4mg allows your GLP-1 receptors to adapt progressively, reducing appetite and promoting feelings of fullness after smaller meals whilst minimising the risk of nausea or vomiting. Each weekly injection maintains steady semaglutide levels, providing consistent appetite regulation throughout the dose progression. The extended 16-week escalation period in Wegovy vs Mounjaro dosing gives your digestive system time to adjust to increased GLP-1 activity, supporting better long-term treatment tolerance. This mechanism-based approach explains why skipping doses or accelerating the schedule can compromise both efficacy and tolerability during your weight management journey.
EverydayMeds Ordering Process for Wegovy vs Mounjaro Dosing
Our streamlined ordering process for Wegovy vs Mounjaro dosing begins with a comprehensive 3-minute clinical assessment covering your medical history, current medications, and weight management goals. Following submission, our prescribing team (GPhC #9012878) reviews your assessment within 3 working days (or 24 hours with express service) to determine the most appropriate starting dose and escalation schedule. Once approved, your medication ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit to preserve medication potency. The process includes automatic reminders for dose progression and reorder notifications, ensuring seamless continuation through your chosen dosing protocol. All communication occurs through your secure patient portal, providing complete transparency throughout your Wegovy vs Mounjaro dosing journey.
Storage and Practical Considerations for Wegovy vs Mounjaro Dosing
Wegovy offers superior storage flexibility in the Wegovy vs Mounjaro dosing comparison, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications use pre-filled FlexTouch injection pens requiring refrigerated storage at 2-8°C before first use, but Wegovy's extended room temperature tolerance provides greater convenience for travel or temporary storage challenges. The once-weekly injection schedule for both treatments aligns with their respective dose escalation timelines, though Wegovy's 5-step progression requires more frequent pen strength changes compared to Mounjaro's 4-step approach. Each pen contains 4 doses (one month's supply), and the dose escalation cannot be accelerated or modified without prescriber approval to maintain safety and efficacy standards. Proper pen technique and injection site rotation remain essential throughout both dosing protocols to ensure optimal medication absorption.
Bundle Savings Strategy for Wegovy vs Mounjaro Dosing Progression
Our strategic approach to Wegovy vs Mounjaro dosing costs includes specially designed bundles that align with each medication's escalation timeline, providing convenience and supply security during your treatment progression. The Wegovy Progress Trio (0.5mg, 1mg, 1.7mg) covers weeks 5-16 for £369.99, eliminating three separate orders and ensuring uninterrupted dose progression through the critical escalation phase. For maintenance dosing, our Ultimate Stability Trio provides three months of 2.4mg supply for £649.99, offering long-term treatment security.
When comparing Wegovy vs Mounjaro dosing bundle options, consider that Wegovy's longer escalation period creates more opportunities for strategic purchasing, whilst Mounjaro's compressed timeline may require different bundling approaches. Our Take-It-Slow bundles accommodate patients who need extended time at lower doses, with options like the Gentle Start Trio (0.25mg, 0.25mg, 0.5mg) for £269.99 supporting extended tolerance-building periods that some prescribers recommend for sensitive patients.
Start Your Wegovy vs Mounjaro Dosing Journey Today
EverydayMeds provides the UK's most transparent and competitive pricing for both Wegovy and Mounjaro dosing protocols, with new customers using code FIRST40 and returning customers applying DOSE25 at checkout to access our published lowest prices. Our clinical team helps you understand the differences between each medication's dosing approach, ensuring you choose the treatment that best aligns with your medical history, lifestyle, and budget considerations. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and secure your starter dose at the UK's best prices. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which dosing protocol is right for your weight management goals. Remember that both treatments are prescription-only medicines requiring clinical assessment and must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
